8-K - APx Acquisition Corp. I (0001868573) (Filer)

8-K - APx Acquisition Corp. I (0001868573) (Filer)

10-Q - APx Acquisition Corp. I (0001868573) (Filer)

10-Q - APx Acquisition Corp. I (0001868573) (Filer)

10-K - APx Acquisition Corp. I (0001868573) (Filer)

8-K - APx Acquisition Corp. I (0001868573) (Filer)

8-K - APx Acquisition Corp. I (0001868573) (Filer)

8-K - APx Acquisition Corp. I (0001868573) (Filer)

8-K - APx Acquisition Corp. I (0001868573) (Filer)

8-K/A - APx Acquisition Corp. I (0001868573) (Filer)

4 - APx Acquisition Corp. I (0001868573) (Issuer)

4 - APx Acquisition Corp. I (0001868573) (Issuer)

4 - APx Acquisition Corp. I (0001868573) (Issuer)

3 - APx Acquisition Corp. I (0001868573) (Issuer)

4 - APx Acquisition Corp. I (0001868573) (Issuer)

4 - APx Acquisition Corp. I (0001868573) (Issuer)

4 - APx Acquisition Corp. I (0001868573) (Issuer)

NASHVILLE, Tenn., Nov. 1, 2024 /PRNewswire/ -- As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ: APXI) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5452(b)(C) (the "Rule"), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the "Notice"). The Company subsequently submitted a plan to regai

NASHVILLE, Tenn., June 5, 2024 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule 5250(c)(1) relating to the Company's obligation to file periodic financi

NASHVILLE, Tenn., March 26, 2024 /PRNewswire/ -- APx Acquisition Corp. I (NASDAQ:APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subject to the approval of APx's shareholders and other customary closing conditions and, upon closing, OmnigenicsAI's shares are expected to be listed on Nas

NASHVILLE, Tenn., Dec. 28, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule 5250(c)(1) relating to the Company's obligation to file periodic financial reports for continued listing. The Letter further stated that the Company has

NASHVILLE, Tenn., Dec. 1, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ:APXI) ("Company"), a publicly traded special purpose acquisition company, announced today that it has signed a non-binding letter of intent ("LOI") for a proposed business combination (the "Business Combination") with a precision medicine company that offers genomic diagnostic tests in clinical genomics, oncology, human microbiome and reproductive genomics, as well as a digital nutrition-based DNA and gut microbiome wellness service that promotes wellbeing and prevents disease ("Target"), that would result in a public listing of the combined company upon completion of the proposed Business Combination.  The Target

APx Acquisition Corp. I ("APx" or the "Company"), a special purpose acquisition company, announced today that at the extraordinary general shareholders meeting held on February 27, 2023, the Company's shareholders voted in favor of proposals to approve an amendment to the Investment Management Trust Agreement, dated December 6, 2021, and the Company's Amended and Restated Memorandum and Articles of Association (the "Amended Articles of Association") to change the payment required to extend the date by which the Company must consummate an initial business combination (the "Combination Period") by two three-month periods. As amended, the required payments are the deposit by the Company into t

APx Acquisition Corp. I (NASDAQ:APXI) ("APx" or the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced that on August 23, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("NASDAQ") advising the Company that the Company did not comply with NASDAQ's Listing Rule 5250(c)(1) for continued listing because NASDAQ had not received the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2022 (the "Form 10-Q"). NASDAQ informed the Company that it has until October 24, 2

APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule 5250(c)(1) relating to the Company's obligation to file periodic financial reports for continued listing. The Letter fu

APx Acquisition Corp. I (NASDAQ:APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subject to the approval of APx's shareholders and other customary closing conditions and, upon closing, OmnigenicsAI's shares are expected to be listed on Nasdaq under the ticker symbol "OMNI".The strategic

  Monday's session saw 175 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Pfizer (NYSE:PFE). The smallest company by market cap to set a new 52-week low was Kiromic BioPharma (NASDAQ:KRBP). Tenon Medical (NASDAQ:TNON) made the largest move down on the session, with shares plummeting 38.98% to reach its 52-week low. Revance Therapeutics (NASDAQ:RVNC) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Stocks that set new 52-week lows on Monday are as follows: Pfizer (NYSE:PFE) shares moved down 1.71% on Monday to hit a new 52-week low of $33.54, drif

APx Acquisition Corp. I (NASDAQ:APXI) (“APx” or the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced that on August 23, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) advising the Company that the Company did not comply with NASDAQ’s Listing Rule 5250(c)(1) for continued listing because NASDAQ had not received the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2022 (the “Form 10-Q”). NASDAQ informed the Company that it has until October 24, 20